398 related articles for article (PubMed ID: 18226845)
1. Application of PBPK modeling in support of the derivation of toxicity reference values for 1,1,1-trichloroethane.
Lu Y; Rieth S; Lohitnavy M; Dennison J; El-Masri H; Barton HA; Bruckner J; Yang RS
Regul Toxicol Pharmacol; 2008 Mar; 50(2):249-60. PubMed ID: 18226845
[TBL] [Abstract][Full Text] [Related]
2. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
3. Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate.
Kirman CR; Sweeney LM; Corley R; Gargas ML
Risk Anal; 2005 Apr; 25(2):271-84. PubMed ID: 15876203
[TBL] [Abstract][Full Text] [Related]
4. Determination of age and gender differences in biochemical processes affecting the disposition of 2-butoxyethanol and its metabolites in mice and rats to improve PBPK modeling.
Corley RA; Grant DM; Farris E; Weitz KK; Soelberg JJ; Thrall KD; Poet TS
Toxicol Lett; 2005 Mar; 156(1):127-61. PubMed ID: 15705493
[TBL] [Abstract][Full Text] [Related]
5. Application of a physiologically based pharmacokinetic model for reference dose and reference concentration estimation for acetone.
Gentry PR; Covington TR; Clewell HJ; Anderson ME
J Toxicol Environ Health A; 2003 Dec; 66(23):2209-25. PubMed ID: 14612334
[TBL] [Abstract][Full Text] [Related]
6. Approaches for applications of physiologically based pharmacokinetic models in risk assessment.
Thompson CM; Sonawane B; Barton HA; DeWoskin RS; Lipscomb JC; Schlosser P; Chiu WA; Krishnan K
J Toxicol Environ Health B Crit Rev; 2008 Aug; 11(7):519-47. PubMed ID: 18584453
[TBL] [Abstract][Full Text] [Related]
7. A comparison of physiologically based pharmacokinetic model predictions and experimental data for inhaled ethanol in male and female B6C3F1 mice, F344 rats, and humans.
Pastino GM; Asgharian B; Roberts K; Medinsky MA; Bond JA
Toxicol Appl Pharmacol; 1997 Jul; 145(1):147-57. PubMed ID: 9221833
[TBL] [Abstract][Full Text] [Related]
8. Tissue dosimetry expansion and cross-validation of rat and mouse physiologically based pharmacokinetic models for trichloroethylene.
Keys DA; Bruckner JV; Muralidhara S; Fisher JW
Toxicol Sci; 2003 Nov; 76(1):35-50. PubMed ID: 12915716
[TBL] [Abstract][Full Text] [Related]
9. Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end points.
Bogen KT; Gold LS
Regul Toxicol Pharmacol; 1997 Feb; 25(1):26-42. PubMed ID: 9056499
[TBL] [Abstract][Full Text] [Related]
10. Final report on the safety assessment of Trichloroethane.
Int J Toxicol; 2008; 27 Suppl 4():107-38. PubMed ID: 19101834
[TBL] [Abstract][Full Text] [Related]
11. Assessing interaction thresholds for trichloroethylene in combination with tetrachloroethylene and 1,1,1-trichloroethane using gas uptake studies and PBPK modeling.
Dobrev ID; Andersen ME; Yang RS
Arch Toxicol; 2001 May; 75(3):134-44. PubMed ID: 11409535
[TBL] [Abstract][Full Text] [Related]
12. Probabilistic dose-response modeling: case study using dichloromethane PBPK model results.
Marino DJ; Starr TB
Regul Toxicol Pharmacol; 2007 Dec; 49(3):285-300. PubMed ID: 17949874
[TBL] [Abstract][Full Text] [Related]
13. Development of an updated PBPK model for trichloroethylene and metabolites in mice, and its application to discern the role of oxidative metabolism in TCE-induced hepatomegaly.
Evans MV; Chiu WA; Okino MS; Caldwell JC
Toxicol Appl Pharmacol; 2009 May; 236(3):329-40. PubMed ID: 19249323
[TBL] [Abstract][Full Text] [Related]
14. Moving from external exposure concentration to internal dose: duration extrapolation based on physiologically based pharmacokinetic derived estimates of internal dose.
Simmons JE; Evans MV; Boyes WK
J Toxicol Environ Health A; 2005 Jun 11-25; 68(11-12):927-50. PubMed ID: 16020185
[TBL] [Abstract][Full Text] [Related]
15. Steady-state solutions to PBPK models and their applications to risk assessment I: Route-to-route extrapolation of volatile chemicals.
Chiu WA; White P
Risk Anal; 2006 Jun; 26(3):769-80. PubMed ID: 16834633
[TBL] [Abstract][Full Text] [Related]
16. Parameters for pyrethroid insecticide QSAR and PBPK/PD models for human risk assessment.
Knaak JB; Dary CC; Zhang X; Gerlach RW; Tornero-Velez R; Chang DT; Goldsmith R; Blancato JN
Rev Environ Contam Toxicol; 2012; 219():1-114. PubMed ID: 22610175
[TBL] [Abstract][Full Text] [Related]
17. Physiologically based pharmacokinetic rat model for methyl tertiary-butyl ether; comparison of selected dose metrics following various MTBE exposure scenarios used for toxicity and carcinogenicity evaluation.
Borghoff SJ; Parkinson H; Leavens TL
Toxicology; 2010 Sep; 275(1-3):79-91. PubMed ID: 20561556
[TBL] [Abstract][Full Text] [Related]
18. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.
Marino DJ; Clewell HJ; Gentry PR; Covington TR; Hack CE; David RM; Morgott DA
Regul Toxicol Pharmacol; 2006 Jun; 45(1):44-54. PubMed ID: 16442684
[TBL] [Abstract][Full Text] [Related]
19. The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene.
Covington TR; Robinan Gentry P; Van Landingham CB; Andersen ME; Kester JE; Clewell HJ
Regul Toxicol Pharmacol; 2007 Feb; 47(1):1-18. PubMed ID: 16901594
[TBL] [Abstract][Full Text] [Related]
20. Using physiologically based pharmacokinetic modeling and benchmark dose methods to derive an occupational exposure limit for N-methylpyrrolidone.
Poet TS; Schlosser PM; Rodriguez CE; Parod RJ; Rodwell DE; Kirman CR
Regul Toxicol Pharmacol; 2016 Apr; 76():102-12. PubMed ID: 26776754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
